THOUSAND OAKS, Calif.–(BUSINESS WIRE)–Beren Therapeutics P.B.C., a leader in cholesterol-trafficking biology and novel cyclodextrin-based therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has approved LEMBAZ™ (adrabetadex), the first medicine to address the underlying cholesterol trafficking defect that causes Niemann-Pick disease, type C (NPC) and the first medicine to improve survival in infantile-onset NPC (I-NPC). LEMBAZ is approved for adults and children wit

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.